Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rigosertib induces cell death of a myelodysplastic syndrome‐derived cell line by <scp>DNA</scp> damage‐induced G2/M arrest

10 Jan 2015

Abstract excerpt

A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain to be clarified. We investigated the in vitro effects of rigosertib on an MDS-derived cell line MDS-L and a myeloid leukemia cell line HL-60. Rigosertib suppressed the proliferation of both HL-60 and MDS-L...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25580850
DOI: 10.1111/cas.12605

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rigosertib induces cell death of a myelodysplastic syndrome‐derived cell line by <scp>DNA</scp> damage‐induced G2/M arrestPMID 25580850Read ↗

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)Semantic proximity Read ↗

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.Semantic proximity Read ↗

ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell linesSemantic proximity Read ↗

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity Read ↗

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer AgentSemantic proximity Read ↗

Mechanism of action of the multikinase inhibitor Foretinib.Semantic proximity Read ↗

Replication-induced DNA damage after PARP inhibition causes G 2 delay, and cell line-dependent apoptosis, necrosis and multinucleationSemantic proximity Read ↗

Mechanism of action of rigosertib does not involve tubulin bindingSemantic proximity Read ↗

The cell cycle checkpoint inhibitors in the treatment of leukemiasSemantic proximity Read ↗

PARP1 depletion induces RIG-I-dependent signaling in human cancer cellsSemantic proximity Read ↗

Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesisSemantic proximity Read ↗

Mechanisms of interferon-induced cell cycle arrestSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.